The Future of Early-Stage NSCLC Treatment: Updates on Neoadjuvant Immunotherapy

Released On
November 30, 2021

Expires On
November 30, 2022

Media Type
Internet

Completion Time
60 minutes

Specialty
Hematology-Oncology

Topic(s)
Lung Cancer, Oncology

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Paradigm Medical Communications, LLC.

 

Supported by an educational grant from Bristol Myers Squibb Company.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity has been designed to address the educational needs of medical oncologists. It may also be of benefit to other healthcare professionals who manage patients with non-small cell lung cancer (NSCLC).

Program Overview

Approximately half of all patients with early-stage NSCLC relapse after treatment with curative intent, which typically includes surgery, radiation, and adjuvant systemic therapy. The success of immune checkpoint inhibitor (ICI) treatment of advanced NSCLC, and the biologic rationale for a more intact locoregional immune system, has resulted in multiple ongoing clinical trials for neoadjuvant ICI therapy. Early data have been released from some of these trials, showing promising results that indicate the treatment paradigm for early-stage NSCLC may be poised for a major shift. Although this is exciting, there are unanswered questions that can only be addressed by clinical trial results, leading to a critical need for education about the potential future of neoadjuvant therapy for early-stage NSCLC, including the latest data from ongoing neoadjuvant ICI clinical trials.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize the latest clinical trial data on neoadjuvant immunotherapy-based regimens for the treatment of early-stage NSCLC
  • Describe potential adverse events that have been associated with neoadjuvant immunotherapy regimens being evaluated for the treatment of early-stage NSCLC

Faculty

Karen Reckamp, MD, MS

Professor, Department of Medicine
Director, Division of Medical Oncology
Associate Director, Clinical Research
Cedars-Sinai Cancer
Los Angeles, CA

Jonathan Spicer, MD, PhD

Associate Professor of Surgery
McGill University
Medical Director, McGill Thoracic Oncology Network
Director, McGill Advanced Thoracic and Upper GI Surgical Oncology Fellowship
Montreal, Quebec, Canada

Accreditation Statement

Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

Paradigm Medical Communications, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PA Continuing Education
PAs may claim a maximum of 1.0 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Disclosures of Conflicts of Interest

In accordance with ACCME requirements on disclosure, faculty and contributors are asked to disclose any financial relationships occurring over the past 24 months with ineligible companies whose products or services are associated with the area of medicine featured in the activity. These relationships are described below. Any potential conflicts of interest have been mitigated.

Karen Reckamp, MD, MS

  • Consultant: Amgen; AstraZeneca; Blueprint Medicines Corporation; Boehringer Ingelheim, Inc.; Calithera Biosciences, Inc.; Eli Lilly and Co; Euclises; Daiichi Sankyo Company, Limited; EMD Soreno; Genentech, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Merck KGaA; Seattle Genetics, Inc.; Takeda Pharmaceutical Company Limited; Tesaro Inc.
  • Research Funding:
    • AbbVie Inc; Acea Therapeutics Inc; Adaptimmune Therapeutics plc; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb Company; Genentech, Inc.; GlaxoSmithKline; Guardant Health; Janssen Pharmaceuticals, Inc; Loxo Oncology; Molecular Partners; Seattle Genetics; Spectrum Pharmaceutical, Inc.; Takeda Pharmaceutical Company Ltd; Xcovery; Zenopharm (funds for each of these paid to City of Hope)
    • Calithera Biosciences, Inc.; Daiichi Sankyo, Inc; Elevation Oncology (funds for each of these paid to Cedars-Sinai)

Jonathan Spicer, MD, PhD

  • Consultant: AstraZeneca; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd; Merck & Co, Inc
  • Research Funding: AstraZeneca; Merck & Co, Inc

Paradigm Medical Communications, LLC staff members have no relevant financial relationships with ineligible companies to disclose.

Independent peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Resolution of Conflict of Interest

Paradigm Medical Communications, LLC has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair and balanced, independent, and aligned with the public interest. Conflicts, if any, are mitigated through one or more processes. All CME content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education.

Instructions for Participation and Credit

To receive a CME certificate of participation, you should:

  1. Follow instructions to register or log in with your professional information and complete the preactivity assessment
  2. View the online activity in its entirety
  3. Complete and submit the online posttest and evaluation. You must answer 70% of the posttest questions correctly to earn credit. You will have unlimited opportunities to successfully complete the posttest

A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.

For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949 or cme@paradigmmc.com.

There is no fee required for participation in this activity.

Course Viewing Requirements

Hardware/Software Requirements
This certified CME activity is designed using HTML5 web components. As you navigate the video using the supplied controls, the slides will sync to the speaker.

Supported Browsers (Desktop/Mobile)
Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+

PDF documents
This activity may contain PDF documents. Most current browsers support viewing of PDFs natively, but you may also download a free version of Adobe Acrobat Reader here: http://get.adobe.com/reader

Technical Support: If you have any technical problems or playback issues, email us at contactus@paradigmmc.com.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.

Disclaimer

This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified. As an ACCME-accredited provider, Paradigm Medical Communications, LLC’s activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.

Terms of Use and Privacy Policy

Disclaimer
The materials provided for this activity are for informational purposes only, and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC accepts no liability for the content referenced in this activity.

Privacy policy
Paradigm Medical Communications, LLC or hosted contracted partner is committed to protecting the privacy of those who participate in the activities located at www.paradigmmc.com (herein referred to as “website”). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.

Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.

Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC to continuously improve the learning experience.

Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants’ credits.

© 2021 Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.

Contact Information

If you have any questions or comments, please email us at contactus@paradigmmc.com.